title: Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.
abstract: BACKGROUND
  The effect of dual infection with herpes simplex virus type 1 (HSV-1) mutants on human oral squamous cell carcinoma (SCC) cells was examined.
  
  
  METHODS
  Human oral SCC cells were infected with gamma1(34.5) gene-deficient HSV-1 R849 and HSV-1 HF that has multiple mutations and induces cell fusion. Cell viability was measured by LDH release assay. Athymic mice were injected with oral SCC cells into the buccal region to induce subcutaneous tumors.
  
  
  RESULTS
  Oral SCC cells were infected with R849, followed by infection with R849 or HF. Virus production was elevated by both strains of HSV-1. Although the release of LDH from R849-infected cells was increased by secondary infection with R849 or HF, the effect of HF was more remarkable. When nude mouse tumors were treated with R849, HF, R849+R849, or R849+HF, treatment with R849+HF was the most effective.
  
  
  CONCLUSIONS
  These results suggest that fusion-inducing virus HF enhances the oncolytic ability of gamma1(34.5) gene-deficient HSV-1 and provides a rationale for using fusogenic viruses as enhancing agents
authors.affiliation: Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan.
authors.forename: Fumi
authors.initials: F
authors.lastname: Ogawa
authors.forename: Hiroo
authors.initials: H
authors.lastname: Takaoka
authors.forename: Soichi
authors.initials: S
authors.lastname: Iwai
authors.forename: Keiko
authors.initials: K
authors.lastname: Aota
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Yura
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000628:therapy* / Q000821:virology; D045744:Cell Line, Tumor; D005260:Female; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000502:physiology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009062:Mouth Neoplasms / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D023041:Xenograft Model Antitumor Assays